Delta 9 Cannabis Competitors

Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) and Delta 9 Cannabis (TSE:DN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Willow Biosciences Inc. (WLLW.TO) and Delta 9 Cannabis, as reported by MarketBeat.

Willow Biosciences Inc. (WLLW.TO) currently has a consensus target price of C$2.25, indicating a potential upside of 78.57%. Delta 9 Cannabis has a consensus target price of C$1.10, indicating a potential upside of 92.98%. Given Delta 9 Cannabis' higher probable upside, analysts plainly believe Delta 9 Cannabis is more favorable than Willow Biosciences Inc. (WLLW.TO).

Profitability

This table compares Willow Biosciences Inc. (WLLW.TO) and Delta 9 Cannabis' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Willow Biosciences Inc. (WLLW.TO) and Delta 9 Cannabis' top-line revenue, earnings per share (EPS) and valuation.

Delta 9 Cannabis has higher revenue and earnings than Willow Biosciences Inc. (WLLW.TO). Delta 9 Cannabis is trading at a lower price-to-earnings ratio than Willow Biosciences Inc. (WLLW.TO), indicating that it is currently the more affordable of the two stocks.

Summary

Delta 9 Cannabis beats Willow Biosciences Inc. (WLLW.TO) on 5 of the 7 factors compared between the two stocks.

MediPharm Labs (TSE:LABS) and Delta 9 Cannabis (TSE:DN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and target prices for MediPharm Labs and Delta 9 Cannabis, as reported by MarketBeat.

MediPharm Labs currently has a consensus target price of C$1.53, indicating a potential upside of 225.53%. Delta 9 Cannabis has a consensus target price of C$1.10, indicating a potential upside of 92.98%. Given MediPharm Labs' higher probable upside, research analysts plainly believe MediPharm Labs is more favorable than Delta 9 Cannabis.

Profitability

This table compares MediPharm Labs and Delta 9 Cannabis' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares MediPharm Labs and Delta 9 Cannabis' top-line revenue, earnings per share (EPS) and valuation.

Delta 9 Cannabis has higher revenue and earnings than MediPharm Labs. Delta 9 Cannabis is trading at a lower price-to-earnings ratio than MediPharm Labs, indicating that it is currently the more affordable of the two stocks.

Khiron Life Sciences (CVE:KHRN) and Delta 9 Cannabis (TSE:DN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.

Profitability

This table compares Khiron Life Sciences and Delta 9 Cannabis' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Khiron Life Sciences and Delta 9 Cannabis' top-line revenue, earnings per share (EPS) and valuation.

Delta 9 Cannabis has higher revenue and earnings than Khiron Life Sciences. Delta 9 Cannabis is trading at a lower price-to-earnings ratio than Khiron Life Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Khiron Life Sciences and Delta 9 Cannabis, as reported by MarketBeat.

Khiron Life Sciences currently has a consensus target price of C$1.20, indicating a potential upside of 155.32%. Delta 9 Cannabis has a consensus target price of C$1.10, indicating a potential upside of 92.98%. Given Khiron Life Sciences' higher probable upside, research analysts plainly believe Khiron Life Sciences is more favorable than Delta 9 Cannabis.

Summary

Delta 9 Cannabis beats Khiron Life Sciences on 4 of the 7 factors compared between the two stocks.

Meta Growth (CVE:META) and Delta 9 Cannabis (TSE:DN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations.

Profitability

This table compares Meta Growth and Delta 9 Cannabis' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Meta Growth and Delta 9 Cannabis' top-line revenue, earnings per share (EPS) and valuation.

Delta 9 Cannabis has lower revenue, but higher earnings than Meta Growth. Delta 9 Cannabis is trading at a lower price-to-earnings ratio than Meta Growth, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Meta Growth and Delta 9 Cannabis, as reported by MarketBeat.com.

Delta 9 Cannabis has a consensus target price of C$1.10, indicating a potential upside of 92.98%. Given Delta 9 Cannabis' higher probable upside, analysts clearly believe Delta 9 Cannabis is more favorable than Meta Growth.

Summary

Delta 9 Cannabis beats Meta Growth on 5 of the 7 factors compared between the two stocks.

48North Cannabis (CVE:NRTH) and Delta 9 Cannabis (TSE:DN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations.

Profitability

This table compares 48North Cannabis and Delta 9 Cannabis' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and price targets for 48North Cannabis and Delta 9 Cannabis, as reported by MarketBeat.com.

Delta 9 Cannabis has a consensus target price of C$1.10, indicating a potential upside of 92.98%. Given Delta 9 Cannabis' higher probable upside, analysts clearly believe Delta 9 Cannabis is more favorable than 48North Cannabis.

Valuation and Earnings

This table compares 48North Cannabis and Delta 9 Cannabis' top-line revenue, earnings per share (EPS) and valuation.

Delta 9 Cannabis has higher revenue and earnings than 48North Cannabis. Delta 9 Cannabis is trading at a lower price-to-earnings ratio than 48North Cannabis, indicating that it is currently the more affordable of the two stocks.

Summary

Delta 9 Cannabis beats 48North Cannabis on 5 of the 7 factors compared between the two stocks.

Delta 9 Cannabis (TSE:DN) and (CSI) (CNSX:CSI) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, analyst recommendations and profitability.

Profitability

This table compares Delta 9 Cannabis and (CSI)'s net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings for Delta 9 Cannabis and (CSI), as provided by MarketBeat.com.

Delta 9 Cannabis currently has a consensus price target of C$1.10, indicating a potential upside of 92.98%.

Valuation and Earnings

This table compares Delta 9 Cannabis and (CSI)'s gross revenue, earnings per share and valuation.

(CSI) has lower revenue, but higher earnings than Delta 9 Cannabis.

Summary

Delta 9 Cannabis beats (CSI) on 2 of the 2 factors compared between the two stocks.